Brokerages Set Agilon Health, Inc. (NYSE:AGL) PT at $2.18

Agilon Health, Inc. (NYSE:AGL) has been assigned a consensus recommendation of “Hold” from the fifteen research firms that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation and three have given a buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $2.1750.

AGL has been the subject of a number of research reports. BTIG Research reaffirmed a “neutral” rating on shares of Agilon Health in a research note on Friday, December 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Agilon Health in a research note on Wednesday, January 21st. Wells Fargo & Company raised their price objective on shares of Agilon Health from $1.00 to $1.50 and gave the company an “overweight” rating in a research note on Friday, February 27th. Barclays decreased their price target on shares of Agilon Health from $1.00 to $0.50 and set an “underweight” rating for the company in a research report on Friday, February 27th. Finally, Royal Bank Of Canada raised Agilon Health from a “hold” rating to a “moderate buy” rating in a research note on Wednesday, December 3rd.

Institutional Trading of Agilon Health

Several hedge funds have recently added to or reduced their stakes in the company. Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new stake in shares of Agilon Health in the 2nd quarter valued at approximately $31,000. Wealthcare Advisory Partners LLC acquired a new position in shares of Agilon Health during the third quarter worth $26,000. CIBC Bancorp USA Inc. purchased a new position in Agilon Health in the third quarter valued at $34,000. Pilgrim Partners Asia Pte Ltd acquired a new stake in Agilon Health in the third quarter valued at $37,000. Finally, Tower Research Capital LLC TRC raised its stake in Agilon Health by 214.0% in the second quarter. Tower Research Capital LLC TRC now owns 37,079 shares of the company’s stock valued at $85,000 after buying an additional 25,270 shares in the last quarter.

Agilon Health Trading Down 11.0%

AGL opened at $0.38 on Friday. The business’s 50 day moving average price is $0.62 and its 200 day moving average price is $0.77. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.02 and a current ratio of 1.02. The stock has a market capitalization of $157.65 million, a PE ratio of -0.40 and a beta of 0.11. Agilon Health has a one year low of $0.34 and a one year high of $6.08.

Agilon Health shares are set to reverse split on the morning of Tuesday, March 31st. The 1-25 reverse split was announced on Wednesday, March 18th. The number of shares owned by shareholders will be adjusted after the market closes on Monday, March 30th.

Agilon Health (NYSE:AGL) last issued its quarterly earnings data on Wednesday, February 25th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.19). Agilon Health had a negative return on equity of 120.82% and a negative net margin of 6.60%.The company had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.46 billion. As a group, equities research analysts expect that Agilon Health will post -0.59 EPS for the current year.

Agilon Health Company Profile

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.